D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex

Area of Science:

• Neuroscience
• Pharmacology
• Cognitive Science

Background:

• Dopamine D1 receptor agonists are known to improve cognitive functions.
• The specific roles of distinct intracellular signaling pathways, such as cAMP and β-arrestin, in mediating these cognitive enhancements remain incompletely understood.
• Functional selectivity, where different ligands preferentially activate specific signaling pathways, offers a way to dissect these roles.

Purpose of the Study:

• To investigate the impact of dopamine D1 receptor agonist functional selectivity on cognitive performance and neurophysiological activity in vivo.
• To compare the effects of 2-methyldihydrexidine (full agonist at cAMP, super-agonist at β-arrestin) and CY208,243 (high intrinsic activity at cAMP, low at β-arrestin) on working memory.

Main Methods:

• Utilized two dopamine D1 agonists, 2-methyldihydrexidine and CY208,243, with differing intrinsic activities and functional selectivity profiles.
• Recorded neuronal firing rates in the prefrontal cortex during a working memory task sensitive to outcome-related information.
• Assessed neurophysiological measures including spike-field coherence and local field potential oscillations, alongside behavioral performance.

Main Results:

• Both agonists altered prefrontal cortex neuronal firing rates, but 2-methyldihydrexidine demonstrated superior effects.
• 2-Methyldihydrexidine enhanced the prospective encoding of task-relevant information and retrospective discrimination of outcomes.
• The superior agonist improved micro-network activity and behavioral outcomes, suggesting a critical role for β-arrestin signaling.

Conclusions:

• Ligand bias in dopamine D1 receptor signaling significantly influences both neurophysiological and behavioral endpoints in an intact animal model.
• Maximal cognitive enhancement via D1 receptor activation is achieved with full, unbiased intrinsic activity or agonists with substantial β-arrestin pathway engagement.
• This study provides novel insights into optimizing D1 agonist-based cognitive therapies by considering functional selectivity.